2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
VanScoy B, Jones S, Conde H, Vincent C, Bhavnani S, Rubino C, Aronin S, Puttagunta S, Ambrose P. 2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model. Open Forum Infectious Diseases 2023, 10: ofad500.2185. PMCID: PMC10678615, DOI: 10.1093/ofid/ofad500.2185.Peer-Reviewed Original ResearchUncomplicated urinary tract infectionsDose-ranging studyVitro infection modelMedical CenterMIC ratioInfection modelNet bacterial stasisUrinary tract infectionPK-PD indexDose fractionation studiesPlasma concentration-time profilesOral drug administrationGrant/research supportOne-compartmentTotal daily exposureConcentration-time profilesDrug-resistant pathogensTract infectionsMIC targetsOral prodrugOrganic anion transport inhibitorBacterial burdenMIC valuesRenal excretionDose selection2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
VanScoy B, Conde H, Vincent C, Bhavnani S, Aronin S, Puttagunta S, Ambrose P. 2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model. Open Forum Infectious Diseases 2023, 10: ofad500.2186. PMCID: PMC10677872, DOI: 10.1093/ofid/ofad500.2186.Peer-Reviewed Original ResearchVitro infection modelUncomplicated urinary tract infectionsDrug-resistant subpopulationsMedical CenterInfection modelUrine concentrationsDrug resistance amplificationMurine thigh modelUrinary tract infectionEscherichia coli clinical isolatesInitial burdenFree drug plasma concentrationSimulated pharmacokinetic profilesFive-day study periodGrant/research supportConcentration-time profilesPO q12hTract infectionsOral prodrugOrganic anion transport inhibitorBacterial burdenControl regimenPharmacodynamic evaluationRenal excretionPlasma concentrations